Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00636792 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
A Phase 2 study of Follicular Lymphoma, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
- 2
- Study locations
NCT00636792 is a Phase 2 study of Follicular Lymphoma that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 73 participants, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (46% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00636792, a Phase 2 study of Follicular Lymphoma, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refractory to prior therapies, including rituximab.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Bendamustine
- DRUG VELCADE
Study Locations (2)
District of Columbia
- Georgetown University Medical Center - Washington D.C.
North Dakota
- MidDakota Clinic - Cancer Treatment and Research Center - Bismarck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00636792
The ClinicalTrials.gov registry entry for NCT00636792 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (46% lower). The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Follicular Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Rituximab is the first listed.
NCT00636792 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, North Dakota.
Frequently Asked Questions
What is clinical trial NCT00636792 about?
NCT00636792 is a clinical study titled "A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma". This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refract...
What is the current status of trial NCT00636792?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2008-02. Estimated completion is 2010-05.
What conditions does trial NCT00636792 study?
This clinical trial studies the following conditions: Follicular Lymphoma.
What interventions are being tested in trial NCT00636792?
The interventions under investigation include: Rituximab (DRUG), Bendamustine (DRUG), VELCADE (DRUG).
Who is sponsoring clinical trial NCT00636792?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00636792 being conducted?
This trial has 2 study locations across District of Columbia, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.